
Opinion|Videos|July 4, 2024
Describing the Value of ctDNA in Clinical Practice
The key opinion leaders share their approaches for communicating about circulating tumor DNA and minimal residual disease to patients, emphasizing the significance of ctDNA testing in detecting MRD.
Advertisement
Episodes in this series

- Mackenzie Phillips: How do you describe ctDNA and MRD to patients?
- Jing Yi: Why do you think it’s important to do ctDNA testing for MRD?
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Matching Neoadjuvant Therapy to Tumor Genomics in High-Risk Prostate Cancer
2
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
3
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
4
Second-Line Options and Selecting Ipilimumab Plus Nivolumab in RCC
5

